Adding bevacizumab to encorafenib and cetuximab for BRAF V600E colorectal cancer
Tests encorafenib, cetuximab and bevacizumab in BRAF V600E colorectal cancer.
Key facts
- Who runs it
- Vall D Hebron Institute Of Oncology
- Where
- A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo, Santander, Valencia, and Zaragoza, SpainSee the 15 sites
- Trial code
- Registry title
- Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 94 people, planned
- Started
- 17 May 2024
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 19 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic colorectal cancer that has a BRAF V600E mutation and has grown after 1 or 2 earlier treatment regimens.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Metastatic colorectal cancer, confirmed by tissue or cell tests. The disease has progressed after 1 or 2 earlier regimens in the metastatic setting.
- Earlier treatment
- Must have had 1 or 2 earlier treatment regimens for metastatic disease, with the disease progressing afterwards.
- Biomarker or test result
- BRAF V600E mutation in tumor tissue. Must be able to receive cetuximab according to the local label, based on tumor RAS status.
Main reasons for not taking part
- Significant vascular disease in the 6 months before cycle 1, day 1
- Bleeding disorder or clinically significant coagulopathy
- Tumors with microsatellite instability or mismatch repair deficiency
- Stomach or bowel problems that may change how encorafenib is absorbed
- Blood clot or stroke-type event in the 6 months before starting treatment
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Histologically- or cytologically-confirmed mCRC that is metastatic
- Presence of BRAF V600E mutation in tumor tissue previously determined according to the guidelines of each center, any time point before the enrollment in the study
- Eligible to receive cetuximab per locally approved label with regard to tumor RAS status, any time point before the enrollment in the study
- Progression of disease after 1 or 2 prior regimens in the metastatic setting
Who cannot take part
- Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Cycle 1, Day 1
- History of thromboembolic or cerebrovascular events ≤ 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary embolism
- Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation)
- Impaired gastrointestinal (GI) function or disease that may significantly alter the absorption of encorafenib (e.g., ulcerative diseases, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption)
- Concurrent or previous other malignancy within 5 years of study entry without Sponsor approval, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy
- Tumors with microsatellite instability or mismatch repair deficiency
Where in Spain
- Complexo Hospitalario Universitario A CoruñaA Coruña, SpainTaking people
- Hospital de la Santa Creu i Sant PauBarcelona, SpainTaking people
- Hospital del MarBarcelona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital Universitario Reina SofiaCórdoba, SpainTaking people
- Institut Catala D'oncologiaL'Hospitalet de Llobregat, SpainTaking people
- Hospital Clínico San CarlosMadrid, SpainTaking people
- Hospital General Universitario Gregorio MarañónMadrid, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- Hospital Universitario Regional de MálagaMálaga, SpainTaking people
- Hospital Universitario Central De AsturiasOviedo, SpainTaking people
- Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
- Hospital Clinico Universitario de ValenciaValencia, SpainTaking people
- Hospital General Universitario de ValenciaValencia, SpainTaking people
- Hospital Unviersitario Miguel ServetZaragoza, SpainTaking people
About the trial
What the trial wants to find out
To evaluate the antitumor activity of the combination of encorafenib, cetuximab and bevacizumab in subjects who have progressed to one or two chemotherapeutic regimens for BRAF V600E-mutant mCRC. For the safety lead-in phase only: To assess the safety and tolerability of the combination of encorafenib, cetuximab and bevacizumab.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial
- Plain-language title
- Adding bevacizumab to encorafenib and cetuximab for BRAF V600E colorectal cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 19 June 2026